tradingkey.logo

Grail Inc

GRAL
查看詳細走勢圖
91.090USD
+2.775+3.14%
收盤 12/19, 16:00美東報價延遲15分鐘
3.29B總市值
虧損本益比TTM

Grail Inc

91.090
+2.775+3.14%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+3.14%

5天

+0.30%

1月

-2.63%

6月

+99.63%

今年開始到現在

+410.31%

1年

+396.40%

查看詳細走勢圖

TradingKey Grail Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Grail Inc當前公司基本面數據相對健康,增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名93/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價105.00。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Grail Inc評分

相關信息

行業排名
93 / 404
全市場排名
209 / 4582
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
105.000
目標均價
+5.21%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Grail Inc亮點

亮點風險
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
業績高增長
公司營業收入穩步增長,連續3年增長126.09%
估值低估
公司最新PE估值-8.54,處於3年歷史低位
機構減倉
最新機構持股24.89M股,環比減少19.54%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉1.71K股

Grail Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Grail Inc簡介

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代碼GRAL
公司Grail Inc
CEORagusa (Robert)
網址https://grail.com/

常見問題

Grail Inc(GRAL)的當前股價是多少?

Grail Inc(GRAL)的當前股價是 91.090。

Grail Inc 的股票代碼是什麼?

Grail Inc的股票代碼是GRAL。

Grail Inc股票的52週最高點是多少?

Grail Inc股票的52週最高點是115.760。

Grail Inc股票的52週最低點是多少?

Grail Inc股票的52週最低點是16.100。

Grail Inc的市值是多少?

Grail Inc的市值是3.29B。

Grail Inc的淨利潤是多少?

Grail Inc的淨利潤為-2.03B。

現在Grail Inc(GRAL)的股票是買入、持有還是賣出?

根據分析師評級,Grail Inc(GRAL)的總體評級為買入,目標價格為105.000。

Grail Inc(GRAL)股票的每股收益(EPS TTM)是多少

Grail Inc(GRAL)股票的每股收益(EPS TTM)是-10.662。
KeyAI